Early trial tests new Pill's power against tough cancers
NCT ID NCT04497116
Summary
This early-phase study tested a new oral drug called RP-3500 (camonsertib) in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe and effective dose, check how the body processes the drug, and see if it could help shrink tumors, either by itself or when combined with two other cancer drugs. The trial enrolled 276 people to help determine if this new approach is worth studying further.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
#1001, The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
#1002, Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
#1003, Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
#1004, Memorial Sloan Kettering Cancer Institute
New York, New York, 10065, United States
-
#1005, Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
#1006, Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
#1007, Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
#1014, Northwestern University
Chicago, Illinois, 60611, United States
-
#2001, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
#3001, The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
#3002, Freeman Hospital Newcastle
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
#3003, Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
#4001, Copenhagen University Hospital Rigshospitalet - Blegdamsvej
Copenhagen, DK, 2100 Ø, Denmark
Conditions
Explore the condition pages connected to this study.